Skip to main content

Table 1 Sociodemographic and clinical characteristics at baseline for all patients and for patients with more than one annual health assessment

From: Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020

 

All

patients

(N = 654)

Patients with

≥2 health assessments

(N = 225)

Age (years), n (%)

 18–29

81 (12)

23 (10)

 30–39

185 (28)

63 (28)

 40–49

205 (31)

75 (33)

 50–59

148 (23)

53 (24)

 ≥ 60

35 (5)

11 (5)

Mean (SD)

43 (11)

44 (10)

Gender, n (%)

 Male

461 (71)

170 (76)

 Female

193 (29)

55 (24)

Highest educational level, n (%)

 Not completed primary school

40 (6)

15 (7)

 Completed primary school (9 years)

286 (44)

105 (47)

 Completed high school (12 years)

259 (40)

81 (36)

 ≤ 3 years of college or university

57 (9)

20 (9)

 >  3 years of college or university

12 (2)

<5 (2)

Receiving opioid agonist therapy, n (%)

537 (82)

205 (91)

OAT opioid (%)

 Methadone

209 (39)

96 (43)

 Buprenorphine/Buprenorphine-naloxone

321 (60)

107 (48)

OAT opioid dose ratio (median (IQR))a

0.9 (0.8–1.1)

1.0 (0.9–1.1)

Housing situation the past 30 days, n (%)

 Stableb

569 (87)

203 (90)

 Unstablec

85 (13)

22 (10)

Injected substances the past 12 months, n (%)

338 (56)

116 (52)

Frequent substance use the past 12 months, n (%)d

 Alcohol

154 (26)

56 (25)

 Benzodiazepines

238 (39)

87 (39)

 Cannabis

313 (52)

124 (55)

 Opioids

97 (16)

27 (12)

 Stimulants (amphetamines and cocaine)

176 (29)

60 (27)

Chronic infectious diseases, n (%)

 Hepatitis C virus infection

315 (48)

184 (82)

  Low virulent (< 800,000 IE/ml)

168 (25)

92 (41)

  High virulent (≥ 800,000 IE/ml)

147 (22)

92 (41)

 Hepatitis B virus infection

5 (0)

<  5 (<  1)

 Human immunodeficiency virus

<  5 (<  1)

<  5 (<  1)

Hematological and biochemical samples, median (IQR)

 Hemoglobin (g/dl)

14 (13–15)

14 (13–15)

 Estimated glomerulus filtration rate (ml/min/1.73 m2)

104 (89–122)

105 (91–124)

 C-reactive protein (mg/L)

4 (1–9)

3 (1–8)

 Aspartate transaminase (U/L)

31 (23–50)

40 (30–65)

Liver stiffness, median (IQR)

 Transient elastography (kPa)

5 (4–7)

6 (5–8)

 Aspartate transaminase to platelets ratio index

0.3 (0.2–0.6)

0.4 (0.3–0.8)

  1. The table displays the sociodemographic and clinical characteristics for all included patients, and for patients with two or more health assessments, including FSS-9 measurements at baseline
  2. FSS-9 nine-item fatigue severity scale (Likert scale), IQR interquartile range, kPa kilopascal, OAT opioid agonist therapy, SD standard deviation
  3. aOAT opioid ratio is a ratio between the received dose of OAT opioids per day and the expected median daily dose (18 mg buprenorphine, 18/4.5 mg buprenorphine-naloxone or 90 mg methadone). A ratio on 1.0 indicates that patients received the expected daily dose; bA stable housing situation was defined as having owned or rented housing situation or being imprisoned; cUnstable housing situation was defined as living in a homeless shelter, with family or friends, or on the street; dFrequent substance use was defined as using substance at least weekly during the past 12 months
Back to article page

Substance Abuse Treatment, Prevention, and Policy

ISSN: 1747-597X